article · Future Science OA
<b>Aim:</b> To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19.<b>Materials & methods:</b> A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treatment period.<b>Results:</b> The results showed that TZV is superior to oseltamivir regarding length of hospital stay, days until clinical symptoms improvement, and cure of chest pneumonia.<b>Discussion:</b> Different literature data indicate the superiority of TZV in treating COVID-19 when compared with other therapeutic agents. While there is controversy about the efficacy of oseltamivir.<b>Conclusion:</b> It was concluded that TZV is more effective than oseltamivir in the management of COVID-19 disease.<b>Trial registration number:</b> NCT04973462.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/20565623.2024.2418798
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
